Catalyst Pharmaceutical Partners ( (CPRX) ) has released its Q1 earnings. Here is a breakdown of the information Catalyst Pharmaceutical Partners presented to its investors.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the development and commercialization of therapies for rare diseases, with a strong focus on patient care and accessibility. The company has a significant presence in the U.S. and is expanding its global footprint.
Catalyst Pharmaceuticals reported a record-breaking first quarter in 2025, with total revenues reaching $141.4 million, marking a 43.6% increase compared to the previous year. This growth was driven by the strong performance of its key products, FIRDAPSE and AGAMREE, and reflects the company’s effective commercial strategy.
The company’s financial performance highlights include a significant increase in GAAP net income to $56.7 million and non-GAAP net income to $86.6 million. FIRDAPSE and AGAMREE were major contributors to revenue, with AGAMREE experiencing a remarkable 1,777.5% increase in sales. Catalyst also strengthened its balance sheet, ending the quarter with $580.7 million in cash and no debt.
Strategically, Catalyst made notable advancements, including the acceptance of AGAMREE’s New Drug Submission by Health Canada and the launch of FIRDAPSE in Japan. The company also settled a patent litigation with Teva Pharmaceuticals, delaying the entry of a generic version of FIRDAPSE in the U.S. until 2035.
Looking ahead, Catalyst Pharmaceuticals remains confident in its full-year 2025 revenue guidance of $545 million to $565 million. The company plans to continue its strategic initiatives to expand its product portfolio and market reach, aiming for sustained long-term growth.